Global Cell Line Development Market Size, Share, Opportunities, COVID 19 Impact, And Trends By Type (Recombinant Cell Lines, Hybridomas, Continuous Cell Lines, Primary Cell Lines), By Source (Mammalian Cell Line Development, Non Mammalian Cell Line Development), By Application (Drug Discovery And Research, Bioproduction, Tissue Engineering & Regenerative Medicine, Toxicity Testing), And By Geography - Forecasts From 2019 To 2024

Published:  May 2021 Report Code: KSI061612090 Pages: 115

The global cell line development market is expected to reach US$4.718 billion by 2024 from US$2.122 billion in 2018 growing at a CAGR of 14.24%. A cell line is a permanently established cell culture that will proliferate indefinitely given appropriate fresh medium and space and is often used in place of primary cells to study biological processes. Cell line development refers to the process of developing stable cell lines for use in a number of important applications including biologics (e.g. recombinant protein and monoclonal antibody) production, drug screening, and gene functional studies. The process of cell line development includes transfection and selection and single-cell cloning. The market is expected to show significant growth during the given forecast period owing to the rise in development and demand for monoclonal antibodies around the globe. The rise in vaccine production and technological innovations in cell line development will also augment the growth of the cell line development market.

However, a strict regulatory framework coupled with the time-consuming process for the development of stable lines might restrain the growth of the market during the given time frame. This research study examines the current market trends related to demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases, and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top-down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global Cell Line Development market value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the global Cell Line Development market.

Major industry players profiled as part of the report are MabPlex Inc., ATUM, and Selexis among others.

Global Cell Line Development Market Scope:

Report Metric Details
 Market size value in 2018  US$2.122 billion
 Market size value in 2024  US$4.718 billion
 Growth Rate  CAGR of 14.24% from 2018 to 2024
 Base year  2018
 Forecast period  2019–2024
 Forecast Unit (Value)  USD Billion
 Segments covered  Type, Source, Application, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered  Lonza, Biofactura, WuXi AppTec, KBI Biopharma, ATUM, Fusion Antibodies plc,   Selexis, In Vivo, Celonic AG, MabPlex Inc.
 Customization scope  Free report customization with purchase

Segmentation

By Type

Recombinant Cell Lines

Hybridomas

Continuous Cell Lines

Primary Cell Lines

 

By Source

Mammalian Cell Line Development

Non Mammalian Cell Line Development

 

By Application

Drug Discovery and Research

Bioproduction

Tissue Engineering & Regenerative Medicine

Toxicity Testing

 

By Geography

North America

United States

Canada

Others

 

South America

Brazil

Argentina

Others

 

Europe

United Kingdom

Germany

France

Others

 

Middle East and Africa

Saudi Arabia

UAE

Israel

Others

 

Asia Pacific

China

India

Australia

South Korea

Others


Frequently Asked Questions (FAQs)

Q1. What will be the cell line development market size by 2024?
A1. The global cell line development market is expected to reach a market size of US$4.718 billion by 2024.
 
Q2. What is the size of global cell line development market?
A2. Cell Line Development market was valued at US$2.122 billion in 2018.
 
Q3. What are the growth prospects for cell line development market?
A3. The global cell line development market is expected to grow at a CAGR of 14.24% during the forecast period.
 
Q4. What factors are anticipated to drive the cell line development market?
A4. Rise in vaccine production and technological innovations in cell line development will also augment the growth of the cell line development market.
 
Q5. Who are the major players in the global cell line development market?
A5. Major industry players profiled as part of the report are MabPlex Inc., ATUM, and Selexis among others.

 

1. Introduction
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. Research Methodology
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. Key Findings of the Study
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. Global Cell Line Development Market Forecast by Type
5.1. Recombinant Cell Lines
5.2. Hybridomas
5.3. Continuous Cell Lines
5.4. Primary Cell Lines
6. Global Cell Line Development Market Forecast by Source
6.1. Mammalian Cell Line Development
6.2. Non Mammalian Cell Line Development 
7. Global Cell Line Development Market Forecast by Geography 
7.1. North America
7.1.1. The U.S
7.1.2. Canada
7.1.3. Mexico
7.1.4. Others
7.2. South America
7.2.1. Brazil 
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. U.K.
7.3.2. France
7.3.3. Germany
7.3.4. Italy
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. UAE
7.4.3. Israel
7.4.4. Others
7.5. Asia Pacific 
7.5.1. China
7.5.2. India
7.5.3. Australia
7.5.4. South Korea
7.5.5. Others 
8. Competitive intelligence
8.1. Competition and Offerings Analysis of Key Vendors
8.2. Strategies of Key Players
8.3. Recent Investments and Deals
9. Company Profiles
9.1. Lonza
9.2. Biofactura
9.3. WuXi AppTec
9.4. KBI Biopharma
9.5. ATUM
9.6. Fusion Antibodies plc
9.7. Selexis
9.8. In Vivo
9.9. Celonic AG
9.10. MabPlex Inc.

Lonza

Biofactura

WuXi AppTec

KBI Biopharma

ATUM

Fusion Antibodies plc

Selexis

In Vivo

Celonic AG

MabPlex Inc.

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us